{"id":232,"date":"2017-03-01T22:23:45","date_gmt":"2017-03-01T22:23:45","guid":{"rendered":"https:\/\/www.mybiosource.com\/learn\/?p=232"},"modified":"2023-03-07T13:51:51","modified_gmt":"2023-03-07T13:51:51","slug":"inovio-pharmas-vaccine-clears-first-hurdle-in-phase-1-trials","status":"publish","type":"post","link":"https:\/\/www.mybiosource.com\/learn\/inovio-pharmas-vaccine-clears-first-hurdle-phase-1-trials\/","title":{"rendered":"Inovio Pharma\u2019s Vaccine Clears First Hurdle In Phase 1 Trials"},"content":{"rendered":"

Table of Contents<\/strong><\/span><\/h2>\n

1. Introduction<\/strong>
\n2. Success of DNA-based Zika Virus Vaccine in Human Trials<\/strong>
\n3. Positive Clinical Data and Safety of Vaccine<\/strong>
\n4. Study Conducted as Low and High Dose Vaccine Groups<\/strong>
\n5. Phase 2 Trials in Puerto Rico <\/strong>
\n6. Monoclonal Antibody Therapies for Immediate Protection<\/strong>
\n7. Zika Infection and Its Link to Medical Conditions and Birth Defects<\/strong>
\n8. Conclusion and Future Prospects<\/strong><\/p>\n

\n

A DNA<\/span>-based Zika virus<\/a> vaccine<\/span> developed by Inovio Pharmaceuticals has proven successful in phase I open-label dose-ranging human trials. In animal studies, this vaccine<\/span> was found to prevent Zika virus<\/span> infection as well as brain damage.\"\"<\/p>\n

In the press release, the company said it is optimistic on developing the first vaccine<\/span> given positive clinical data in humans. Apart from inducing a strong immune response, the candidate vaccine<\/span> was found to be safe among the study participants.<\/p>\n

The study was conducted as low dose and high dose vaccine<\/span> groups and both demonstrated Zika antigen<\/span>-specific antibody responses. The phase ran for around 60 weeks for evaluating the safety, tolerability and induction and persistence of Zika specific antibody and T cell<\/span> responses.<\/p>\n

The company is expected to commence 2nd phase 1 trials in Puerto Rico that would include 160 test participants. Nearly 35000 people living Puerto Rico are reportedly infected with Zika virus<\/span>.<\/p>\n

In addition to vaccine<\/span> development, the company also bagged $8.8 million grant from the Bill & Melinda Gates Foundation to develop a DNA<\/span>-based monoclonal antibody<\/span> to provide protection against Zika infection and ensuing complications. Therapies based on monoclonal antibodies provide immediate protection but cannot be used as a long-term option for protection. Health experts believe administering monoclonal antibody<\/span> and vaccine<\/span> together would ideally protect the recipient immediately.<\/p>\n

It is a well-known fact that Zika infection during pregnancy is known to cause microcephaly<\/span> to the unborn child. Also, Zika has been linked to numerous medical conditions<\/a> such as Guillain-Barr\u00e9 Syndrome and damage to the retina<\/span>. The most common symptoms of Zika are fever, rash, joint pain, conjunctivitis<\/span>, muscle pain, and Headache.<\/p>\n

There are at least three vaccines developed by different groups and organization awaiting to enter human trials for their Zika vaccine<\/span> candidates, notably protein Sciences and Bharat Biotech.<\/p>\n","protected":false},"excerpt":{"rendered":"

Table of Contents 1. Introduction 2. Success of DNA-based Zika Virus Vaccine in Human Trials 3. Positive Clinical Data and Safety of Vaccine 4. Study Conducted as Low and High Dose Vaccine Groups 5. Phase 2 Trials in Puerto Rico 6. Monoclonal Antibody Therapies for Immediate Protection 7. Zika Infection and Its Link to Medical […]<\/p>\n","protected":false},"author":2,"featured_media":233,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2],"tags":[6,7],"class_list":["post-232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-outbreaks","tag-dna-vaccine","tag-zika-vaccine"],"_links":{"self":[{"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/posts\/232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/comments?post=232"}],"version-history":[{"count":0,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/posts\/232\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/media\/233"}],"wp:attachment":[{"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/media?parent=232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/categories?post=232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/tags?post=232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}